A muscarinic antagonist used to treat drug-induced parkinsonism and to relieve pain from muscle spasm.

Removal of a drug from the market due to the identification of an intrinsic property of the drug that results in a serious risk to public health.

A macrolide antibiotic that is similar to ERYTHROMYCIN.

Drugs that bind to but do not activate CHOLINERGIC RECEPTORS, thereby blocking the actions of ACETYLCHOLINE or cholinergic agonists.

Drugs that bind to but do not activate MUSCARINIC RECEPTORS, thereby blocking the actions of endogenous ACETYLCHOLINE or exogenous agonists. Muscarinic antagonists have widespread effects including actions on the iris and ciliary muscle of the eye, the heart and blood vessels, secretions of the respiratory tract, GI system, and salivary glands, GI motility, urinary bladder tone, and the central nervous system.